                         SEQUENCE LISTING

<110>  OREGON HEALTH & SCIENCE UNIVERSITY
 
<120>  TUMOR ANTIGEN-SPECIFIC T CELL RESPONSES

<130>  4153.012PC01

<150>  US 62/858,756
<151>  2019-06-07

<150>  US 62/878,511
<151>  2019-07-25

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  1

Val Met Ala Pro Arg Thr Leu Leu Leu 
1               5                   


<210>  2
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  2

Ala Arg Ala Ala Ser Leu Ser Leu Gly Phe Leu Phe Leu Leu Phe 
1               5                   10                  15  


<210>  3
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  3

Lys Glu Leu Lys Phe Val Thr Leu Val Phe Arg His Gly Asp Arg 
1               5                   10                  15  


<210>  4
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  4

Gln Leu Thr Gln Leu Gly Met Glu Gln His Tyr Glu Leu Gly Glu 
1               5                   10                  15  


<210>  5
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  5

Leu Asn Glu Ser Tyr Lys His Glu Gln Val Tyr Ile Arg Ser Thr 
1               5                   10                  15  


<210>  6
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  6

Asn His Met Lys Arg Ala Thr Gln Met Pro Ser Tyr Lys Lys Leu 
1               5                   10                  15  


<210>  7
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  7

Met Val Leu Leu Phe Ile His Ile Arg Arg Gly Pro Cys Trp Gln 
1               5                   10                  15  


<210>  8
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  8

Val Pro Glu Pro Ala Ser Gln His Thr Leu Arg Ser Gly Pro Gly 
1               5                   10                  15  


<210>  9
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  9

Ser Ala Glu Arg Leu Gln Gly Arg Arg Ser Arg Gly Ala Ser Gly 
1               5                   10                  15  


<210>  10
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  10

Ile Asp Glu Ser Leu Ile Phe Tyr Lys Lys Trp Glu Leu Glu Ala 
1               5                   10                  15  


<210>  11
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  11

Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu Lys His Lys Leu Asp 
1               5                   10                  15  


<210>  12
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  12

Phe Met Lys Leu Arg Thr Asp Ala Val Leu Pro Leu Thr Val Ala 
1               5                   10                  15  


<210>  13
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  13

Leu Gln Gly Arg Arg Ser Arg Gly Ala Ser Gly Ser Glu Pro Gln 
1               5                   10                  15  


<210>  14
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide

<400>  14

His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln 
1               5                   10                  15  


